Alemtuzumab (Lemtrada)
Alemtuzumab (Lemtrada) is a medication administered by two IV infusions, separated by one year, for the treatment of relapsing forms of MS. Alemtuzumab binds to CD52, a cell surface antigen present on T and B lymphocytes, and on natural killer cells, monocytes, and macrophages. Following cell surface binding to T and B lymphocytes, alemtuzumab results in antibody-dependent cellular cytolysis and complement-mediated lysis. Because of its safety profile, the use of alemtuzumab should generally be reserved for people who have had an inadequate response to two or more drugs indicated for the treatment of MS.
Additional Information
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
